产前晚期早产儿类固醇试验对产前皮质类固醇给药的影响
该研究分析2016年1月1日至2018年12月31日美国出生证明数据,采用中断时间序列设计,评估产前晚期早产儿类固醇研究的发表或指南变化与晚期早产儿产前皮质类固醇给药率的关系。结果显示,晚期早产儿给药率显著增加(调整后发病率比1.48,95%CI 1.36-1.61,P=.00),足月儿也显著增加,而32+0至33+6周及28+0至31+6周组无显著变化。
要点
- 晚期早产儿产前皮质类固醇给药率在研究发表后显著增加(调整后发病率比1.48,95%CI 1.36-1.61,P=.00)。
- 足月儿产前皮质类固醇给药率也显著增加,存在不必要的暴露。
- 32+0至33+6周及28+0至31+6周组的给药率无显著变化。
核心结论
- 产前晚期早产儿类固醇研究的在线发表与美国晚期早产儿产前皮质类固醇给药率立即且持续增加相关,表明该研究指南快速成功转化为临床实践。
- 然而,足月儿接受产前皮质类固醇治疗出现不必要的增加。
- 鉴于产前皮质类固醇治疗的长期后果尚未阐明,应努力尽量减少不必要的婴儿暴露。
研究设计与样本
- 研究分析了2016年1月1日至2018年12月31日公开可用的美国出生证明数据。
- 采用中断时间序列设计,分析产前晚期早产儿类固醇研究的发表与晚期早产(34+0至36+6周)每月产前皮质类固醇给药率变化之间的关联。
- 以28+0至31+6周妊娠分娩作为对照,并探索32+0至34+6周以及足月(>37周)分娩的给药情况。
- 回归模型允许分析阶梯变化和斜率变化,选择2016年2月作为干预期。
- 总样本量为18,031,950例分娩,其中34+0至36+6周分娩1,056,047例,28+0至31+6周123,788例,32至33周153,708例,足月分娩16,602,699例,<28周分娩95,708例。
主要发现
- 产前晚期早产儿类固醇研究在线发表后,晚期早产儿产前皮质类固醇给药率出现统计学显著增加(调整后发病率比1.48;95%置信区间1.36-1.61;P=.00)。
- 足月儿产前皮质类固醇给药率在研究发表后也显著增加。
- 32+0至33+6周或28+0至31+6周妊娠年龄组的产前皮质类固醇给药率无显著变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2016 the Antenatal Late Preterm Steroids study was published, demonstrating that antenatal corticosteroid therapy given to women at risk of late preterm delivery reduces respiratory morbidity in infants. However, the administration of antenatal corticosteroid therapy in late-preterm infants remains controversial. Late-preterm infants do not suffer from the same rates of morbidity as early-preterm infants, and the short-term benefits of antenatal corticosteroid therapy are less pronounced; consequently, the risk of possible harm is more difficult to balance. OBJECTIVE: This study aimed to evaluate the association between the publication of the Antenatal Late Preterm Steroids study or the subsequent changes in guidelines and the rates of antenatal corticosteroid therapy administration in late-preterm infants in the United States. STUDY DESIGN: Data analyzed were publicly available US birth certificate data from January 1, 2016 to December 31, 2018. An interrupted time series design was used to analyze the association between publication of the Antenatal Late Preterm Steroids study and changes in monthly rates of antenatal corticosteroid administration in late preterm gestation (34+0 to 36+6 weeks). Births at 28+0 to 31+6 weeks' gestation were used as a control. Antenatal corticosteroid therapy administration in women with births at 32+0 to 34+6 weeks was explored to analyze whether the intervention influenced antenatal corticosteroid therapy administration in women in the subgroup approaching 34 weeks' gestation. Antenatal corticosteroid therapy administration in women with term births (>37 weeks' gestation) was analyzed to explore if the intervention influenced the number of term babies exposed to antenatal corticosteroid therapy. Our regression model allowed analysis of both step and slope changes. February 2016 was chosen as the intervention period. RESULTS: Our sample size was 18,031,950 total births. Of these, 1,056,047 were births at 34+0 to 36+6 weeks' gestation, 123,788 at 28+0 to 31+6 weeks, 153,708 at 32 to 33 weeks, and 16,602,699 were term births. There were 95,708 births at <28 weeks' gestation. There was a statistically significant increase in antenatal corticosteroid therapy administration rates in late preterm births following the online publication of the Antenatal Late Preterm Steroids study (adjusted incidence rate ratio, 1.48; 95% confidence interval, 1.36-1.61; P=.00). A significant increase in antenatal corticosteroid therapy administration rates was also seen in full-term births following the online publication of the Antenatal Late Preterm Steroids study. No significant changes were seen in antenatal corticosteroid administration rates in gestational age groups of 32+0 to 33+6 weeks or 28+0 to 31+6 weeks. CONCLUSION: Online publication of the Antenatal Late Preterm Steroids study was associated with an immediate and sustained increase in the rates of antenatal corticosteroid therapy administration in late preterm births across the United States, demonstrating a swift and successful implementation of the Antenatal Late Preterm Steroids study guidance into clinical practice. However, there is an unnecessary increase in full-term infants receiving antenatal corticosteroid therapy. Given that the long-term consequences of antenatal corticosteroid therapy are yet to be elucidated, efforts should be made to minimize the number of infants unnecessarily exposed to antenatal corticosteroid therapy.
引用
- Kearsey EOR, Been JV, Souter VL, et al. The impact of the Antenatal Late Preterm Steroids trial on the administration of antenatal corticosteroids. Am J Obstet Gynecol. 2022. PMID: 35341727. doi:10.1016/j.ajog.2022.03.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。